Inventor · disambiguated record
Markus Mandler
Also filed as: MANDLER MARKUS
12 granted patents·15 pending applications·16 citations·filing 2009–2023
86Inventor score
Files withAFFIRIS AG10MANDLER MARKUS6ADVANTAGE THERAPEUTICS INC4TRIDEM BIOSCIENCE GMBH & CO KG3AC IMMUNE SA2
Top patents by PatentIndex Score
27 records- 0180US11147873B2Treatment of Alzheimer's Disease (AD) with an aluminum saltADVANTAGE THERAPEUTICS INC·Filed 2020·Granted Oct 19, 2021·1 cites·14 claims
- 0280US8613931B2Compounds for treating beta-amyloidosesMANDLER MARKUS·Filed 2009·Granted Dec 24, 2013·8 cites·15 claims
- 0376US10646565B2Treatment of alzheimer'S disease (AD) with an aluminum saltAFFIRIS AG·Filed 2015·Granted May 12, 2020·1 cites·19 claims
- 0475US11065273B2Treatment and prevention of alzheimer's disease (AD)AFFIRIS AG·Filed 2015·Granted Jul 20, 2021·1 cites·15 claims
- 0575US9724399B2Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disordersMANDLER MARKUS·Filed 2009·Granted Aug 8, 2017·3 cites·13 claims
- 0675US2024148782A1Treatment and prevention of alzheimer's disease (ad)ADVANTAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0774US2023201320A1Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathyAC IMMUNE SA·Filed 2022·Application pending·0 cites
- 0873US11534484B2Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathyAC IMMUNE SA·Filed 2019·Granted Dec 27, 2022·0 cites·9 claims
- 0971US11857568B2Treatment and prevention of Alzheimer's disease (AD)ADVANTAGE THERAPEUTICS INC·Filed 2021·Granted Jan 2, 2024·0 cites·19 claims
- 1070US10517935B2Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disordersAFFIRIS AG·Filed 2016·Granted Dec 31, 2019·1 cites·10 claims
- 1166US8409581B2Compounds for treating amyloidosesMANDLER MARKUS·Filed 2009·Granted Apr 2, 2013·1 cites·4 claims
- 1266US2022062412A1Treatment of alzheimer's disease (ad) with an aluminum saltADVANTAGE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1361US2025186580A1A CONJUGATE COMPRISING AT LEAST A ß-GLUCANTRIDEM BIOSCIENCE GMBH & CO KG·Filed 2023·Application pending·0 cites
- 1461US2025186595A1A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNANTRIDEM BIOSCIENCE GMBH & CO KG·Filed 2023·Application pending·0 cites
- 1560US2011092436A1Compounds for treating symptoms associated with parkinson's diseaseAFFIRIS AG·Filed 2009·Application pending·0 cites
- 1653US2025186596A1A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNANTRIDEM BIOSCIENCE GMBH & CO KG·Filed 2023·Application pending·0 cites
- 1753US2015093432A1CompositionAFFIRIS AG·Filed 2013·Application pending·0 cites
- 1852US9964547B2Method for detecting aSyn-specific antibodies in a biological sampleAFFIRIS AG·Filed 2014·Granted May 8, 2018·0 cites·19 claims
- 1952US2013287807A1Compounds for treating symptoms associated with parkinson's diseaseMANDLER MARKUS·Filed 2013·Application pending·0 cites
- 2051US2016008443A1METHOD FOR TREATING A beta-AMYLOIDOSISAFFIRIS AG·Filed 2015·Application pending·0 cites
- 2150US2015093431A1CompositionsAFFIRIS AG·Filed 2013·Application pending·0 cites
- 2248US2020369738A1Treatment of Local Skin Hypotrophy ConditionsACCANIS BIOTECH F&E GMBH & CO KG·Filed 2018·Application pending·0 cites
- 2344US2013230545A1Compounds for treating beta-amyloidosesMANDLER MARKUS·Filed 2013·Application pending·0 cites
- 2442US2020038487A1Prevention and treatment of non-melanoma skin cancer (nmsc)ACCANIS BIOTECH F&E GMBH & CO KG·Filed 2018·Application pending·0 cites
- 2542US2015306194A1Method for treating a synucleiopathyAFFIRIS AG·Filed 2015·Application pending·0 cites
- 2641US10478454B2Treatment of Alzheimer's disease (AD) with aluminum oxyhydroxideAFFIRIS AG·Filed 2015·Granted Nov 19, 2019·0 cites·12 claims
- 2728US8828942B2Means for treating synucleinopathiesMANDLER MARKUS·Filed 2010·Granted Sep 9, 2014·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Markus Mandler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →